Mainz Biomed N.V. is a Germany based molecular genetics cancer diagnostic company. The Company operates under one segment, namely genetic diagnostic testing services. Its portfolio consists of various products and product candidates, such as ColoAlert, a colorectal cancer (CRC) screening stool-based DNA (deoxyribonucleic acid) test; PancAlert, a stool-based screening test for the detection of pancreatic cancer; GenoStrip, a platform technology to detect pathogens in environments on a molecular genetic basis. The Company competes with Exact Sciences, Epigenomics AG, Novigenix SA, GRAIL, Inc. and Agena Biosciences Inc.
Ticker SymbolMYNZ
Company nameMainz Biomed NV
IPO dateNov 04, 2021
CEOMr. Guido Baechler
Number of employees19
Security typeOrdinary Share
Fiscal year-endNov 04
AddressSirius Gutenberg Park
CityMAINZ
Stock exchangeNASDAQ Capital Market Consolidated
CountryGermany
Postal code55129
Phone4961315542860
Websitehttps://www.mainzbiomed.com/
Ticker SymbolMYNZ
IPO dateNov 04, 2021
CEOMr. Guido Baechler
A total of
0.00
USD has been distributed in dividends over the past 5 years.

No Data